Short Interest in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Grows By 112.1%

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 54,264 shares, an increase of 112.1% from the December 15th total of 25,588 shares. Based on an average trading volume of 468,130 shares, the short-interest ratio is presently 0.1 days. Currently, 0.5% of the shares of the company are sold short. Currently, 0.5% of the shares of the company are sold short. Based on an average trading volume of 468,130 shares, the short-interest ratio is presently 0.1 days.

Radiopharm Theranostics Stock Down 0.2%

Shares of RADX traded down $0.01 during trading hours on Friday, reaching $5.14. 24,134 shares of the company traded hands, compared to its average volume of 61,567. The stock has a fifty day simple moving average of $4.98 and a 200 day simple moving average of $5.29. Radiopharm Theranostics has a fifty-two week low of $3.50 and a fifty-two week high of $16.25.

Analyst Ratings Changes

Several research firms have issued reports on RADX. B. Riley reaffirmed a “buy” rating and set a $16.00 price objective (up from $13.00) on shares of Radiopharm Theranostics in a report on Tuesday, December 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $15.33.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Radiopharm Theranostics stock. PNC Financial Services Group Inc. lifted its position in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,000 shares of the company’s stock after acquiring an additional 8,000 shares during the period. PNC Financial Services Group Inc. owned about 0.20% of Radiopharm Theranostics worth $88,000 at the end of the most recent reporting period.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.